Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Amarin updates Q1 revenue guidance and updates on REDUCE-IT study progress and Vascepa promotion initiatives

Published 04/04/2018, 08:13 AM
Updated 04/04/2018, 08:13 AM
© Reuters.  Amarin updates Q1 revenue guidance and updates on REDUCE-IT study progress and Vascepa promotion initiatives
  • Amarin Corporation (NASDAQ:AMRN) announces an update to its Q1 revenue guidance, progress of REDUCE-IT study, and initiation of Vascepa promotion initiatives.
  • Amarin estimates its Q1 net product revenue to be ~$43M, an increase of 25% to 30% over Q1 2017. Previous estimated net product revenue was $45 to $48M.
  • New prescriptions (NRx) of Vascepa reached record levels in March 2018 based on data from Symphony Health and IQVIA. The Company's expanded Vascepa promotion and disease awareness Initiatives is on track.
  • Amarin plans to report top-line results from REDUCE-IT study before the end of Q3. The company intends to provide further updates and anticipates to report 10-Q in early May.
  • Shares are down 3% premarket.
  • Previously: Amarin's REDUCE-IT study hits event target, topline data Q3 (April 4)
  • Now read: Amarin: A Solid Finish To 2017


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.